Shionoiri H, Miyakawa T, Takasaki I, Ishikawa Y, Hiroto S, Kaneko Y, Shindo Y
J Cardiovasc Pharmacol. 1987 Feb;9(2):160-4. doi: 10.1097/00005344-198702000-00006.
We conducted a prospective evaluation of the effects of chronic captopril therapy on glucose tolerance in 8 nondiabetic, hypertensive patients and 6 hypertensive patients with impaired glucose tolerance, including 3 diabetic patients. Captopril was well tolerated by all patients, and no untoward effects were observed. Chronic captopril therapy produced a significant decrease in blood pressure in all patients. No patients with normal glucose tolerance developed diabetes mellitus. Neither fasting nor post-glucose-load venous plasma glucose deteriorated in any patients during chronic captopril therapy. There were no significant changes in the insulinogenic index (delta IRI/delta BS at 30 min post-glucose load) in patients with either normal or impaired glucose tolerance. These results suggest that, in addition to its antihypertensive effect, chronic captopril therapy does not compromise glucose metabolism in hypertensive patients. Thus, captopril may have a clinical advantage in that it apparently can be given safely to hypertensive patients with either normal or impaired glucose metabolism.
我们对8例非糖尿病高血压患者和6例糖耐量受损的高血压患者（包括3例糖尿病患者）进行了一项关于慢性卡托普利治疗对糖耐量影响的前瞻性评估。所有患者对卡托普利耐受性良好，未观察到不良反应。慢性卡托普利治疗使所有患者的血压显著降低。糖耐量正常的患者均未发生糖尿病。在慢性卡托普利治疗期间，任何患者的空腹及葡萄糖负荷后静脉血浆葡萄糖均未恶化。糖耐量正常或受损患者的胰岛素生成指数（葡萄糖负荷后30分钟的ΔIRI/ΔBS）均无显著变化。这些结果表明，除了其降压作用外，慢性卡托普利治疗不会损害高血压患者的糖代谢。因此，卡托普利可能具有临床优势，因为显然它可以安全地用于糖耐量正常或受损的高血压患者。
